Abstract | BACKGROUND: METHODOLOGY/PRINCIPAL FINDINGS:
Miltefosine was orally administered for 27 patients with MA resistant ACL with approved L.tropica infection, at a dosage of ∼2.5 mg/kg daily for 28 days. Patients were evaluated on day 14 and 28, as well as 3, 6 and 12 month post treatment follow up sessions. Laboratory data were performed and repeated at each visit. Data were analyzed using SPSS version 17. Twenty-seven patients including 16 men (59.25%) and 11 women (40.74%) with mean age of 28.56 ± 4.8 (range 3-54 years old) were enrolled. Total number of lesions were 42 (1-4 in each patient). Most of lesions were on face (76.19%). Mean lesions' induration size was 2.38 ± 0.73 cm at the base-line which significantly decreased to1.31 ± 0.58 cm and 0.61 ±0.49 cm after 14 and 28 days of therapy, respectively (p value <0.05). At 12-months follow-up post treatment, 22 patients had definite/partial cure (81.48%) including 17 definitely cured patients, corresponding to a cure rate of 68% on per protocol analysis, and 62.96% according to intention to treat analysis. Recurrence of lesion was only occurred in one patient (3.70%). Nausea was the most subjective complication during the therapy (33.33%). CONCLUSION: Oral miltefosine could be an effective alternative for the treatment of MA-resistant ACL.
|
Authors | Masoumeh Tayyebi, Emadodin Darchini-Maragheh, Pouran Layegh, Bita Kiafar, Vahid Mashayekhi Goyonlo |
Journal | PLoS neglected tropical diseases
(PLoS Negl Trop Dis)
Vol. 15
Issue 3
Pg. e0009241
(03 2021)
ISSN: 1935-2735 [Electronic] United States |
PMID | 33739976
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiprotozoal Agents
- Phosphorylcholine
- miltefosine
- Meglumine Antimoniate
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Antiprotozoal Agents
(therapeutic use)
- Child
- Child, Preschool
- Drug Resistance
- Female
- Humans
- Leishmaniasis, Cutaneous
(drug therapy)
- Male
- Meglumine Antimoniate
(therapeutic use)
- Middle Aged
- Phosphorylcholine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Young Adult
|